Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,226
Out of 4,944 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $37.93 | +10.73% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $145.74 | +157.31% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $74.27 | +54.84% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $86.48 | +6.38% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $16.82 | -28.66% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $9.10 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $38.34 | +134.74% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $247.07 | +9.28% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $91.79 | -25.92% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $10.75 | +318.60% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $122.92 | +123.72% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $28.21 | +31.16% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $79.96 | -24.96% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $102.50 | -65.85% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $308.68 | -73.76% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $37.93
Upside: +10.73%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $145.74
Upside: +157.31%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $74.27
Upside: +54.84%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $86.48
Upside: +6.38%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $16.82
Upside: -28.66%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.10
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $38.34
Upside: +134.74%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $247.07
Upside: +9.28%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $91.79
Upside: -25.92%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $10.75
Upside: +318.60%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $122.92
Upside: +123.72%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $28.21
Upside: +31.16%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $79.96
Upside: -24.96%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $102.50
Upside: -65.85%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $308.68
Upside: -73.76%